HadAB/InhA=IN-1

HadAB/InhA=IN-1 (compound 6e) potently inhibits the enzymatic activity of Mycobacterium tuberculosis InhA, with an IC₅₀ value of 0.81 μM^[1].
HadAB/InhA=IN-1 inhibits the growth of Mycobacterium tuberculosis H37Rv, ethA-deficient strain 81.10, and clinical isolates IC1 and IC2, with an MIC of 1.25 μg/mL (2.9 μM for H37Rv)^[1].
HadAB/InhA=IN-1 maintains stable inhibitory activity against Mycobacterium tuberculosis H37Ra strains overexpressing InhA or KasB (MIC of 0.62 μg/mL), but shows reduced activity against strains overexpressing HadABC (MIC of 1.25 μg/mL), which confirms its targeting of InhA and indicates its interaction with HadABC^[1].
HadAB/InhA=IN-1 (1.25-125 μg/mL; incubation period supporting mycolic acid synthesis) inhibits mycolic acid synthesis in Mycobacterium tuberculosis H37Rv in a dose-dependent manner, and complete inhibition is achieved at concentrations 10 to 100 times its MIC of 1.25 μg/mL^[1].
HadAB/InhA=IN-1 is metabolized by recombinant Mycobacterium tuberculosis EthA, with a metabolic rate of 0.49 min^−1[1].
HadAB/InhA=IN-1 (100 μM; 20 min) forms a covalent adduct with the HadA subunit of Mycobacterium tuberculosis following EthA activation, which is confirmed by ultraviolet-visible spectroscopy and mass spectrometry^[1].
HadAB/InhA=IN-1 (2.5 mM; 2 h) binds to Mycobacterium tuberculosis InhA-NAD⁺ via specific stacking and hydrogen-bonding interactions, as confirmed by X-ray crystallography^[1].
HadAB/InhA=IN-1 (72 h) exhibits cytotoxicity against human HCT116, CACO2, HepG2 and WI38hTERT cell lines, with IC₅₀ values ranging from 3.27 to 43.82 μM and selectivity indices of 1.1 to 15.1^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.